Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
First Claim
1. A method of reducing peripheral blood glucose levels in a mammal, the method comprising intranasally administering a KATP channel activator to the hypothalamus of the mammal in an amount effective to reduce peripheral blood glucose levels in the mammal.
2 Assignments
0 Petitions
Accused Products
Abstract
Provided are methods of increasing KATP channel activity in the hypothalamus of a mammal, methods of reducing glucose production in a mammal, methods of reducing peripheral glucose levels in a mammal, methods of reducing triglyceride levels in a mammal, methods of reducing very low density lipoprotein (VLDL) levels in a mammal, methods of methods of reducing gluconeogenesis in the liver of a mammal, methods of treating metabolic disorders such as diabetes, hyperglycemia, insulin resistance, glucose intolerance, metabolic syndrome and/or obesity, and methods of increasing glucose production and peripheral glucose levels in a mammal. Also provided are methods of treating heart failure, ischemia, coronary heart disease, familial lipoprotein lipase deficiency, hypopituitarism, hyperlipidemia, hypertriglyceridemia, hyperVLDLemia, atherosclerosis, hypercholesterolemia, hypertension, polycystic ovary syndrome, gonadotropin deficiency and/or amenorrhea.
-
Citations
104 Claims
- 1. A method of reducing peripheral blood glucose levels in a mammal, the method comprising intranasally administering a KATP channel activator to the hypothalamus of the mammal in an amount effective to reduce peripheral blood glucose levels in the mammal.
-
20. A method of reducing glucose production in a mammal, the method comprising intranasally administering a KATP channel activator to the hypothalamus of the mammal in an amount effective to reduce glucose production in the mammal.
-
21-38. -38. (canceled)
-
39. A method of reducing gluconeogenesis in the liver of a mammal, the method comprising intranasally administering a KATP channel activator to the hypothalamus of the mammal in an amount effective to reduce hepatic gluconeogenesis in the mammal.
-
40. A method of reducing serum triglyceride levels in a mammal, the method comprising intranasally administering a KATP channel activator to the hypothalamus of the mammal in an amount effective to reduce serum triglyceride levels in the mammal.
-
41-53. -53. (canceled)
-
54. A method of reducing serum very low density lipoprotein (VLDL) levels in a mammal, the method comprising intranasally administering a KATP channel activator to the hypothalamus of the mammal in an amount effective to reduce serum VLDL levels in the mammal.
-
55-67. -67. (canceled)
-
68. A method of treating a disorder in a mammal selected from the group consisting of obesity, type 2 diabetes, type 1 diabetes, hyperglycemia, insulin resistance, glucose intolerance, leptin resistance, metabolic syndrome, heart failure, ischemia, coronary heart disease, familial lipoprotein lipase deficiency, hypopituitarism, hyperlipidemia, hypertriglyceridemia, hyperVLDLemia, atherosclerosis, hypercholesterolemia, hypertension, and any combination of the foregoing, comprising intranasally administering a KATP channel activator to the hypothalamus of the mammal in an amount effective to treat the disorder.
-
69-85. -85. (canceled)
-
86. A method of increasing KATP channel activity in the hypothalamus of a mammal, the method comprising intranasally administering a KATP channel activator to the mammal in an amount effective to increase KATP channel activity in the hypothalamus.
-
87-96. -96. (canceled)
-
97. A pharmaceutical composition formulated for intranasal administration comprising a KATP channel activator in a pharmaceutically acceptable carrier.
-
98. A method of increasing peripheral blood glucose levels in a mammal, the method comprising intranasally administering a KATP channel inhibitor to the hypothalamus of the mammal in an amount effective to increase peripheral blood glucose levels in the mammal.
-
99-103. -103. (canceled)
-
104. A pharmaceutical composition formulated for intranasal administration comprising a KATP channel activator in a pharmaceutically acceptable carrier.
Specification